1. Dipòsit Digital de la Universitat de Barcelona
  2. Recerca
  3. Farmàcia, Tecnologia Farmacèutica i Fisicoquímica
  4. Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/183031
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPérez-González, Noelia-
dc.contributor.authorBozal de Febrer, Núria-
dc.contributor.authorCalpena Campmany, Ana Cristina-
dc.contributor.authorNardi Ricart, Anna-
dc.contributor.authorRodríguez Lagunas, María José-
dc.contributor.authorMorales-Molina, José A.-
dc.contributor.authorSoriano-Ruiz, José L.-
dc.contributor.authorFernández Campos, Francisco-
dc.contributor.authorClares Naveros, Beatriz-
dc.date.accessioned2022-02-10T10:22:36Z-
dc.date.available2022-02-10T10:22:36Z-
dc.date.issued2021-12-12-
dc.identifier.issn2310-2861-
dc.identifier.urihttps://hdl.handle.net/2445/183031-
dc.description.abstractVulvovaginal candidiasis (VVC) poses a significant problem worldwide affecting women from all strata of society. It is manifested as changes in vaginal discharge, irritation, itching and stinging sensation. Although most patients respond to topical treatment, there is still a need for increase the therapeutic arsenal due to resistances to anti-infective agents. The present study was designed to develop and characterize three hydrogels of chitosan (CTS), Poloxamer 407 (P407) and a combination of both containing 2% caspofungin (CSP) for the vaginal treatment of VVC. CTS was used by its mucoadhesive properties and P407 was used to exploit potential advantages related to increasing drug concentration in order to provide a local effect. The formulations were physically, mechanically and morphologically characterized. Drug release profile and ex vivo vaginal permeation studies were performed. Antifungal efficacy against different strains of Candida spp. was also evaluated. In addition, tolerance of formulations was studied by histological analysis. Results confirmed that CSP hydrogels could be proposed as promising candidates for the treatment of VVC-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/gels7040259-
dc.relation.ispartofGels, 2021, num. 7, p. 259-
dc.relation.urihttps://doi.org/10.3390/gels7040259-
dc.rightscc-by (c) Pérez-González, Noelia et al., 2021-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)-
dc.subject.classificationCandidiasi-
dc.subject.classificationMalalties de l'aparell genital femení-
dc.subject.classificationMedicaments antifúngics-
dc.subject.otherCandidiasis-
dc.subject.otherFemale reproductive system diseases-
dc.subject.otherAntifungal agents-
dc.titleNew Formulations Loading Caspofungin for Topical Therapy of Vulvovaginal Candidiasis-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec716403-
dc.date.updated2022-02-10T10:22:36Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
Articles publicats en revistes (Bioquímica i Fisiologia)

Files in This Item:
File Description SizeFormat 
716403.pdf4.56 MBAdobe PDFView/Open
Show simple item record


This item is licensed under a Creative Commons License Creative Commons